TARSUS PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
TARSUS PHARMACEUTICALS, INC. (TARS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 48.99 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 31.64K shares, a 62.50% increase year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 17.35K shares, a 47.98% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 52.83K shares, a 75.24% decline from fiscal 2024.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 213.35K shares, a 21.28% increase from fiscal 2023.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 175.91K shares, a 277.23% increase from fiscal 2022.
- TARSUS PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 46.63K shares, a 18.85% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 31.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 48.99K shares 10-Q · filed 2026-08-06 | 48.99K shares derived: sum of 3 quarters · filed 2026-08-06 | 48.99K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 17.35K shares 10-Q · filed 2026-05-06 | 17.35K shares derived: sum of 2 quarters · filed 2026-05-06 | 17.35K shares derived: sum of 3 quarters · filed 2026-05-06 | 36.82K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-23 | 19.47K shares derived: sum of 3 quarters · filed 2026-02-23 | 52.83K shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 19.47K shares derived: sum of 2 quarters · filed 2025-11-04 | 52.83K shares 10-Q · filed 2025-11-04 | 54.68K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 19.47K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 52.83K shares 10-Q · filed 2025-08-06 | 54.68K shares derived: sum of 3 quarters · filed 2025-08-06 | 77.19K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 33.36K shares 10-Q · filed 2025-05-01 | 35.21K shares derived: sum of 2 quarters · filed 2025-05-01 | 57.72K shares derived: sum of 3 quarters · filed 2025-05-01 | 119.38K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 1.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | 24.36K shares derived: sum of 2 quarters · filed 2025-02-25 | 86.02K shares derived: sum of 3 quarters · filed 2025-02-25 | 213.35K shares 10-K · filed 2025-02-25 |
| 2024-09-30 | 22.51K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 84.17K shares derived: sum of 2 quarters · filed 2024-11-13 | 211.49K shares 10-Q · filed 2024-11-13 | 216.02K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 61.66K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 188.98K shares 10-Q · filed 2024-08-08 | 193.51K shares derived: sum of 3 quarters · filed 2024-08-08 | 195.72K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 127.33K shares 10-Q · filed 2024-05-08 | 131.85K shares derived: sum of 2 quarters · filed 2024-05-08 | 134.07K shares derived: sum of 3 quarters · filed 2024-05-08 | 278.58K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 4.53K shares derived: 10-K 12 month − 3 quarters · filed 2024-02-27 | 6.74K shares derived: sum of 2 quarters · filed 2024-02-27 | 151.25K shares derived: sum of 3 quarters · filed 2024-02-27 | 175.91K shares 10-K · filed 2024-02-27 |
| 2023-09-30 | 2.21K shares 10-Q · filed 2023-11-09 | 146.73K shares derived: sum of 2 quarters · filed 2023-11-09 | 171.38K shares derived: sum of 3 quarters · filed 2023-11-09 | |
| 2023-06-30 | 144.51K shares 10-Q · filed 2023-11-09 | 169.17K shares derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2023-03-31 | 24.65K shares 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | 46.63K shares 10-K · filed 2024-02-27 | |||
| 2021-12-31 | 57.46K shares 10-K · filed 2023-03-17 | |||
| 2020-12-31 | 4.61K shares 10-K · filed 2022-03-14 | |||
| 2019-12-31 | 1.91K shares 10-K · filed 2021-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |